MedMira (MIR.V) Stock Price

MedMira Price

TSX·CLOSED
0.05
​
Market closed

Revenue at MedMira has contracted by 10.8% per year over the past 19 years to 240,509.00 CAD. For MedMira, the net margin of -1,881.2% is down versus -31.5% a few years ago.

MedMira stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MedMira business model & stock analysis

MedMira Inc. is a Canadian company specializing in the development and marketing of innovative diagnostic products. It was founded in 1993 and is headquartered in Halifax, Nova Scotia. MedMira initially focused on HIV testing and developed the first rapid test kits, which proved to be highly effective and reliable. The company later expanded its product line to include diagnostics for Hepatitis and Syphilis. MedMira has become a leading provider of rapid test kits for infectious diseases, with its products being sold globally and proven to be reliable and effective in numerous studies. The company is constantly seeking new technologies and methods to expand its offerings and provide better solutions to its customers. MedMira's business model revolves around the development and marketing of diagnostic products for the medical and pharmaceutical markets. The company collaborates with leading companies and institutions in the industry to develop new products and improve existing solutions. MedMira has different divisions focused on its various diagnostic products, such as HIV, Hepatitis, and Syphilis. Each division has a dedicated team of experts focused on developing and marketing solutions tailored to meet customer needs. The company offers a wide range of products tailored to the needs of different customers and markets, including rapid test kits, ELISA kits, and other diagnostic tools. It specializes in serving specific target groups, such as pregnant women or newborns, and constantly strives to deliver better results to its customers. One example of a product from MedMira is the Reveal G4 Combo Rapid HIV-Syphilis Test, a highly accurate rapid test that detects both HIV and Syphilis infections. The test can be conducted quickly and provides results comparable to traditional tests. MedMira prides itself on being an innovative company focused on customer needs and constantly seeking new ways to improve diagnostics. It has built an excellent reputation and enjoys the trust of leading companies and institutions in the medical and pharmaceutical sectors.

Frequently asked questions about MedMira

MedMira Inc, a leading medical technology company, operates on a business model focused on the development and commercialization of rapid diagnostic solutions. Through extensive research and innovation, MedMira creates advanced tests for infectious diseases, including HIV, hepatitis, and other sexually transmitted infections. These tests are designed to provide accurate and reliable results in a shorter timeframe, enabling healthcare professionals to make informed decisions swiftly. MedMira Inc collaborates with healthcare providers, governments, and distributors worldwide to ensure the widespread availability and accessibility of their diagnostic solutions, ultimately improving patient outcomes and contributing to global health initiatives.

MedMira Inc is primarily active in the medical diagnostics and biotechnology industries.

The main competitors of MedMira Inc in the market include companies like Abbott Laboratories, OraSure Technologies, and Chembio Diagnostics.

MedMira Inc is a Canadian biotech company specializing in the development and commercialization of rapid diagnostic testing solutions. Founded in 1993, MedMira has gained global recognition for its innovative technologies in infectious disease detection, particularly with regards to HIV and hepatitis C. With a commitment to advancing healthcare accessibility, MedMira has developed a range of rapid testing products that deliver accurate results in a matter of minutes. These tests have found applications in both clinical and non-clinical settings, including hospitals, clinics, blood banks, and research laboratories. MedMira Inc continues to be at the forefront of diagnostic testing solutions, driving advancements in the field of healthcare.

MedMira Inc. has achieved several significant milestones in its history. Firstly, the company developed and commercialized its rapid HIV test, the Reveal G4, which offers quick and accurate results in just three minutes. This breakthrough in technology has helped in detecting HIV infections and preventing their spread. Additionally, MedMira Inc. received regulatory approvals from the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and the European Commission (CE Mark) for its innovative product. These milestones have positioned MedMira Inc. as a leader in the field of rapid diagnostics and underscore its commitment to improving global healthcare.

MedMira Inc is primarily present in multiple countries and regions worldwide. The company has a global presence, with its products and services being recognized in North America, Europe, Asia, and Africa. MedMira Inc has successfully established a strong foothold in the United States and Canada, where it continues to expand its market share. Additionally, the company has made significant strides in penetrating international markets, including Europe and Asia. With its commitment to delivering innovative healthcare solutions, MedMira Inc aims to provide its products to healthcare professionals and customers globally.

MedMira Inc represents values of innovation, integrity, and commitment to global health. The company's corporate philosophy revolves around developing and delivering innovative, rapid diagnostic solutions that improve healthcare outcomes worldwide. MedMira Inc's dedication to scientific excellence, stringent quality control, and customer satisfaction has positioned them as a trusted leader in the diagnostic industry. With a focus on precision and accuracy, MedMira Inc strives to provide diagnostic tools and technologies that surpass industry standards, ultimately enhancing patient care and contributing to better healthcare practices globally.

Converted at the current exchange rate, the MedMira share trades at 0.03 EUR (0.05 CAD).

The MedMira share (MIR.V) is listed on 4 stock exchanges, including: Toronto (MIR.V), Frankfurt (47M.F), München (47M.MU).

MedMira Inc is an internationally active biotechnology company from Canada, specializing in the development, manufacture, and marketing of diagnostic rapid tests for infectious diseases. The company's business model is based on the production and sale of various products used in different areas of healthcare. The broad product portfolio of MedMira includes rapid tests for professional use in clinical laboratories as well as for home use. The company's various divisions focus on the production of diagnostic tests for HIV, hepatitis B and C, syphilis, and other infectious diseases. MedMira produces both individual test kits for direct use by medical personnel and complex systems for use in clinical facilities. The company's focus is on reducing the cost of infection testing without compromising on quality and reliability. An important part of MedMira's business model is research and development of new products. The constant work on new testing methods and technologies allows the company to constantly stay up to date with its products and stand out from the competition. In addition to selling rapid tests, MedMira also offers training and consultations for medical personnel. The goal is to improve understanding of infectious diseases and the importance of early detection tests. Through close collaboration with international development and distribution partners, MedMira has access to various markets and can offer its products worldwide. The company strongly focuses on the needs of end users and providing customized solutions. Overall, MedMira's successful business model is based on a combination of high-quality production capacity, efficient distribution and marketing, and continuous research and development. The company stands for high ethical responsibility and aims to contribute to the improvement of global health.

The revenue cannot currently be calculated for MedMira.

The profit cannot currently be calculated for MedMira.

The P/E ratio cannot be calculated for MedMira at the moment.

The P/S cannot be calculated for MedMira currently.

The Eulerpool Quality Score for MedMira is 4/10.

The ISIN of MedMira is CA58501R1029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of MedMira is 932414. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of MedMira is MIR.V. The ticker symbol is used to trade MedMira shares on the stock exchange.

Fair ValueTerminal
0.04 CAD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
3,700.14 CAD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website medmira.com
Country
Currency
CAD
Initial public offering
Dec 1, 1999
ISIN
CA58501R1029
Cusip
58501R102
Sedol
2526399
Market capitalization
35.09 M CADMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
22.02 %
Last updated Nov 19, 2026, 8:41 AM

MedMira Ticker

FRANKFURT · 47M.FMUNICH · 47M.MUOTC · MMIRFTSX · MIR.V

MedMira FIGI

MIR:CN · BBG000C4CX65MIR:CV · BBG000C4CYF3MIR:CJ · BBG000C4D0N7MIR:TV · BBG000C4D1C7MIR:TN · BBG000C4D2K6MIR:TG · BBG000C4D2X2MIR:TK · BBG000C4D3B4MMIRF:US · BBG000CND368MMIRF:UV · BBG000CND9Y447M:GR · BBG000KLXPM447M:GF · BBG000KLXQC347M:GS · BBG000KLXST1

All fundamentals and in-depth analysis of MedMira

Our stock analysis for MedMira stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MedMira. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.